JPWO2021202604A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202604A5 JPWO2021202604A5 JP2022560227A JP2022560227A JPWO2021202604A5 JP WO2021202604 A5 JPWO2021202604 A5 JP WO2021202604A5 JP 2022560227 A JP2022560227 A JP 2022560227A JP 2022560227 A JP2022560227 A JP 2022560227A JP WO2021202604 A5 JPWO2021202604 A5 JP WO2021202604A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- cell
- lipid particle
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 180
- 239000002245 particle Substances 0.000 claims description 133
- 150000002632 lipids Chemical class 0.000 claims description 130
- 239000013598 vector Substances 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 68
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 108091006027 G proteins Proteins 0.000 claims description 49
- 102000030782 GTP binding Human genes 0.000 claims description 49
- 108091000058 GTP-Binding Proteins 0.000 claims description 49
- 108091033319 polynucleotide Proteins 0.000 claims description 49
- 102000040430 polynucleotide Human genes 0.000 claims description 49
- 239000002157 polynucleotide Substances 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 241000035314 Henipavirus Species 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 37
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 36
- 101710091045 Envelope protein Proteins 0.000 claims description 36
- 101710188315 Protein X Proteins 0.000 claims description 36
- 101000930679 Nipah virus Fusion glycoprotein F0 Proteins 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 230000008685 targeting Effects 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 20
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 19
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 18
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- 101000785948 Homo sapiens Asialoglycoprotein receptor 2 Proteins 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 14
- 101000785944 Homo sapiens Asialoglycoprotein receptor 1 Proteins 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000005229 liver cell Anatomy 0.000 claims description 12
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 claims description 10
- 102100026293 Asialoglycoprotein receptor 2 Human genes 0.000 claims description 10
- 239000000232 Lipid Bilayer Substances 0.000 claims description 10
- 210000003494 hepatocyte Anatomy 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 241000893570 Hendra henipavirus Species 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 230000009395 genetic defect Effects 0.000 claims description 7
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- 102100024630 Asc-type amino acid transporter 1 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 102100030651 Glutamate receptor 2 Human genes 0.000 claims description 4
- 101710087631 Glutamate receptor 2 Proteins 0.000 claims description 4
- 102100030668 Glutamate receptor 4 Human genes 0.000 claims description 4
- 101710087627 Glutamate receptor 4 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000866286 Homo sapiens Excitatory amino acid transporter 1 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 241000526636 Nipah henipavirus Species 0.000 claims description 4
- 102000012977 SLC1A3 Human genes 0.000 claims description 4
- 108091006242 SLC7A10 Proteins 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 210000001130 astrocyte Anatomy 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 230000004988 N-glycosylation Effects 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 210000005170 neoplastic cell Anatomy 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108010083359 Antigen Receptors Proteins 0.000 claims description 2
- 102000006306 Antigen Receptors Human genes 0.000 claims description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 2
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 2
- 102100023733 Ephrin-B3 Human genes 0.000 claims description 2
- 108010044085 Ephrin-B3 Proteins 0.000 claims description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004779 membrane envelope Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 description 15
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 11
- 101000658584 Homo sapiens Transmembrane 4 L6 family member 5 Proteins 0.000 description 8
- 102100034898 Transmembrane 4 L6 family member 5 Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 6
- 102000051193 human ASGR2 Human genes 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 108010041397 CD4 Antigens Proteins 0.000 description 3
- 108010032795 CD8 receptor Proteins 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 102000051237 human ASGR1 Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 108700042658 GAP-43 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102220032988 rs281865408 Human genes 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003168P | 2020-03-31 | 2020-03-31 | |
| US63/003,168 | 2020-03-31 | ||
| US202163154341P | 2021-02-26 | 2021-02-26 | |
| US63/154,341 | 2021-02-26 | ||
| PCT/US2021/024993 WO2021202604A1 (fr) | 2020-03-31 | 2021-03-30 | Particules lipidiques ciblées et leurs compositions et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521663A JP2023521663A (ja) | 2023-05-25 |
| JPWO2021202604A5 true JPWO2021202604A5 (fr) | 2024-04-10 |
Family
ID=75639978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560227A Pending JP2023521663A (ja) | 2020-03-31 | 2021-03-30 | 標的化脂質粒子及び組成物ならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210353543A1 (fr) |
| EP (1) | EP4127144A1 (fr) |
| JP (1) | JP2023521663A (fr) |
| KR (1) | KR20230006819A (fr) |
| CN (1) | CN116096866A (fr) |
| AU (1) | AU2021248815A1 (fr) |
| CA (1) | CA3178308A1 (fr) |
| IL (1) | IL296621A (fr) |
| MX (1) | MX2022012191A (fr) |
| WO (1) | WO2021202604A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240028975A (ko) * | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | Cd8-특이적 항체 구조체들 및 이의 조성물 |
| WO2022261150A2 (fr) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Systèmes d'administration de particules |
| WO2023133595A2 (fr) * | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés |
| WO2023150647A1 (fr) * | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Procédés d'administration et de dosage répétés de particules lipidiques ou de vecteurs viraux et systèmes et utilisations connexes |
| WO2024081936A1 (fr) * | 2022-10-13 | 2024-04-18 | Northwestern University | Procédés d'assemblage de vaccins nanoporteurs conjugués à des protéines |
| WO2024119157A1 (fr) * | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation |
| WO2024186695A2 (fr) * | 2023-03-03 | 2024-09-12 | Trustees Of Boston University | Fusion de cellules immunitaires (icf) et ses utilisations |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| PT1895010E (pt) | 1997-12-22 | 2012-01-25 | Oxford Biomedica Ltd | Vectores com base no vírus da anemia infecciosa equina (eiav) |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| KR102243575B1 (ko) | 2010-12-09 | 2021-04-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| AU2012308205A1 (en) | 2011-09-16 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| US9486539B2 (en) | 2012-03-26 | 2016-11-08 | The Regents Of The University Of California | Nipah virus envelope pseudotyped lentiviruses and methods of their use |
| WO2014076137A1 (fr) | 2012-11-13 | 2014-05-22 | Lötvall Jan | Administration d'un agent thérapeutique |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| WO2016077639A2 (fr) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Thérapies nanovésiculaires |
| SG10202008883SA (en) | 2016-03-15 | 2020-10-29 | Codiak Biosciences Inc | Therapeutic membrane vesicles |
| EP3235908A1 (fr) * | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Procédés pour moduler de manière sélective l'activité des sous-types distinctes de cellules |
| EP3558355A2 (fr) * | 2016-12-23 | 2019-10-30 | CureVac AG | Vaccin contre l'hénipavirus |
| CN110869507A (zh) * | 2017-05-08 | 2020-03-06 | 旗舰先锋创新V股份有限公司 | 促进膜融合的组合物和其用途 |
| JP7237960B2 (ja) * | 2017-10-30 | 2023-03-13 | ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー | 標的細胞の選択的形質導入のためのアダプターベースのレトロウイルスベクター系 |
| BR112020023015A2 (pt) * | 2018-05-15 | 2021-02-17 | Flagship Pioneering Innovations V, Inc. | composições de fusossoma e usos das mesmas |
| BR112021000145A2 (pt) * | 2018-07-09 | 2021-04-06 | Flagship Pioneering Innovations V, Inc | Composições de fusossoma e usos das mesmas |
| WO2020102503A2 (fr) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Compositions de fusosome pour administration à des lymphocytes t |
| SG11202105079QA (en) * | 2018-11-14 | 2021-06-29 | Flagship Pioneering Innovations V Inc | Fusosome compositions for cns delivery |
-
2021
- 2021-03-30 MX MX2022012191A patent/MX2022012191A/es unknown
- 2021-03-30 EP EP21720890.9A patent/EP4127144A1/fr active Pending
- 2021-03-30 US US17/218,025 patent/US20210353543A1/en active Pending
- 2021-03-30 KR KR1020227037815A patent/KR20230006819A/ko unknown
- 2021-03-30 AU AU2021248815A patent/AU2021248815A1/en active Pending
- 2021-03-30 CA CA3178308A patent/CA3178308A1/fr active Pending
- 2021-03-30 IL IL296621A patent/IL296621A/en unknown
- 2021-03-30 CN CN202180038773.7A patent/CN116096866A/zh active Pending
- 2021-03-30 JP JP2022560227A patent/JP2023521663A/ja active Pending
- 2021-03-30 WO PCT/US2021/024993 patent/WO2021202604A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5553989B2 (ja) | ウィルスベクターを使用した標的化遺伝子送達方法 | |
| CN107002084B (zh) | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 | |
| AU2022201263B2 (en) | Chimeric antigen receptors and uses thereof | |
| JP2019150066A5 (fr) | ||
| CN116426490A (zh) | 淋巴细胞转导及其扩增调节的方法与组合物 | |
| JP2019122380A (ja) | Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用 | |
| JP7221049B2 (ja) | レンチウイルス調製物の安定化のための緩衝液 | |
| WO1997018318A1 (fr) | Procede d'introduction de genes dans des cellules cibles au moyen de retrovirus | |
| US9090908B2 (en) | Chimeric glycoproteins and pseudotyped lentiviral vectors | |
| JP2021500909A (ja) | 標的細胞の選択的形質導入のためのアダプターベースのレトロウイルスベクター系 | |
| WO2016208754A1 (fr) | Récepteur antigénique immunisant anti-glypicane-1 | |
| TW201840587A (zh) | 嵌合抗原受體 | |
| TW202330909A (zh) | 轉基因免疫效應細胞、其製備方法、慢病毒、構建體、癌症治療藥物及其應用 | |
| EP4448775A1 (fr) | Glycoprotéines de fixation de paramyxoviridae modifiées | |
| JPWO2021202604A5 (fr) | ||
| US5925548A (en) | Modified receptors that continuously signal | |
| WO1998047916A9 (fr) | Polypeptides bifonctionnels utilises dans le ciblage viral specifique en fonction des cellules | |
| JP7189770B2 (ja) | 遺伝子導入細胞の製造方法 | |
| CA2445013A1 (fr) | Polypeptides d'un recepteur de lymphocytes t alpha/beta des murides specifique de la proteine hdm2, acides nucleiques les codant et leur utilisation | |
| JPWO2019236577A5 (fr) | ||
| WO2005024027A1 (fr) | Medicament anticorps | |
| WO2024153120A1 (fr) | Fragment d'ectodomaine pd1 muté, car le contenant et cellule nk | |
| WO2024131966A1 (fr) | Cellule immunitaire modifiée et son utilisation | |
| CN118085085A (zh) | 抗fgfr4单克隆抗体、fgfr4为靶点的嵌合抗原受体t细胞及其应用 | |
| CN118108840A (zh) | 抗fgfr4单克隆抗体、靶向fgfr4的嵌合抗原受体t细胞及其应用 |